Expanding access to CSL’s products through partnerships CSL recognises collaboration and working in partnerships as a key enabler of advancing global health equity. The Company has established many long-term partnerships with numerous organisations, including with the World Federation of Hemophilia (WFH). As part of this partnership, since 2009, CSL has been donating both products and financial contributions to the WFH’s Humanitarian Aid Program, which delivers life-changing treatment to people with limited access to haemophilia A care across developing countries. To enable WFH to widely distribute this life-saving therapy, CSL specifically manufactures this product for donation to WFH, with an increased shelf life of three years. Helping expand access to both acute and preventative prophylaxis treatment, the program aims to reduce bleeding events and improve surgical outcomes. To date, the program has treated over 13,500 acute bleeds, supported more than 7,550 individuals and enabled ongoing prophylaxis for over 1,990 people with bleeding disorders on prophylaxis, strengthening care capabilities in 49 countries. See how CSL’s donations have supported care in Uzbekistan in the case study on page 28. Through partnerships, CSL is also expanding existing programs and helping to establish new initiatives to improve access to products for iron deficiency and to treat anaemia. At the end of FY2024/25, CSL announced an aspirational commitment to treat up to 450,000 people with anaemia in at least three low- and middle-income countries by FY2030, with CSL Vifor’s FERINJECT®. Since this announcement, CSL has been progressing this commitment, working with existing regional partners that support healthcare delivery in low- and middle-income countries, while also exploring new partnerships and program opportunities focused on reaching underserved and vulnerable populations with unmet medical needs. Several initiatives advanced into early implementation during the FY2026 year, including programs in Africa and South America. In these regions, CSL has established targeted programs to better understand local patient needs and identify barriers to care, with the objective of developing scalable, sustainable solutions that improve access to treatment and health outcomes. See how CSL is helping patients in rural Egypt access anaemia treatment below. Case Study – Improving access for anaemia treatment in rural Egypt According to the World Health Organization (WHO) Global Anaemia Estimates Report 2025, anaemia leads to harmful intergenerational consequences including adverse pregnancy and birth outcomes, higher mortality and morbidity risks, and poor cognitive and motor development in children. The WHO report also outlines that, in women aged 15–49 years, by pregnancy status, anaemia remains a major public health concern. Affordability remains a key barrier to accessing optimal treatment for anaemia in low- and middle-income countries, particularly among self-pay patients in rural and underserved communities. Physicians have anecdotally reported that in some instances, patients were purchasing only partial doses of FERINJECT® when a full dose was clinically required for treatment. Limited financial resources were forcing patients to make difficult trade-offs, impacting their treatment quality and ability to adhere to recommended dosing, highlighting a critical gap between clinical guidelines and real-world patient access. To address this challenge, and to help drive better health outcomes for patients, CSL joined the Egypt Affordability Outreach Program this year in partnership with a large pharmaceutical company. The program aims to support low-income populations in rural regions with equitable access to better treatment options. Through this program, CSL is providing its iron infusion product, FERINJECT®, at a discounted price through a ‘two-for-one’ affordability model, enabling patients to access the full prescribed dose needed for treatment at a reduced cost. CSL is also providing financial funding to increase awareness and improve education across different stakeholder groups in ensuring optimal dosing is maintained and full, not partial, treatment is undertaken. The program first commenced in April 2026 and has already assisted treatment of 2,500 patients. As the roll-out of the program continues, by enhancing equitable access to its products to vulnerable and underserved communities, CSL aims to improve the health outcomes of patients – patients can receive the full course of treatment they need without compromising their health due to cost – while also empowering rural physicians to confidently prescribe optimal doses, knowing affordability barriers are mitigated. 27 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3